Finance

Lists
001067:KRX
JW Pharmaceutical(2Pb) Pref Shs
â‚©49,650.00
0.00%
(0.00) 1D
Sep 9, 9:00:30 AM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 001067...
Open
â‚©49,650
High
â‚©49,650
Low
â‚©49,650
Mkt. cap
640.88B
Avg. vol.
67.00
Volume
80.00
Dividend
1.31%
Quarterly dividend
â‚©163
Ex-dividend date
Dec 27, 2024
P/E ratio
16.76
52-wk high
â‚©61,500
52-wk low
â‚©38,500
EPS
â‚©2,962
Shares outstanding
209.97K
No. of employees
1K
Open
â‚©49,650
High
â‚©49,650
Low
â‚©49,650
Mkt. cap
640.88B
Avg. vol.
67.00
Volume
80.00
Dividend
1.31%
Quarterly dividend
â‚©163
Ex-dividend date
Dec 27, 2024
P/E ratio
16.76
52-wk high
â‚©61,500
52-wk low
â‚©38,500
EPS
â‚©2,962
Shares outstanding
209.97K
No. of employees
1K
About JW Pharmaceutical(2Pb) Pref Shs
CEOLee, Kyung Ha
Employees1.07K
Founded1945
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in KRW
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in KRW
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
200.02B
198.94B
199.88B
222.02B
Cost of goods sold
105.39B
109.09B
101.43B
116.73B
Cost of revenue
105.39B
109.09B
101.43B
116.73B
Research and development expenses
7.33B
15.27B
9.38B
11.86B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
55.58B
60.42B
55.91B
59.90B
Operating expense
62.60B
80.98B
64.88B
71.95B
Total operating expenses
167.99B
190.07B
166.31B
188.68B
Operating income
32.03B
8.87B
33.58B
33.34B
Other non operating income
-4.64B
8.03B
1.21B
835.27M
EBT including unusual items
27.85B
17.49B
35.20B
34.76B
EBT excluding unusual items
27.85B
15.96B
35.20B
34.76B
Income tax expense
-2.74B
2.18B
7.72B
6.86B
Effective tax rate
-9.83%
12.44%
21.93%
19.75%
Other operating expenses
-
-
-
-
Net income
30.59B
15.32B
27.48B
27.89B
Net profit margin
15.29%
7.70%
13.75%
12.56%
Earnings per share
1.27K
-
-
-
Interest and investment income
-
3.34B
-
-
Interest expense
-
-4.42B
-
-
Net interest expenses
-
-1.09B
-
-
Depreciation and amortization charges
-
-
-
-
EBITDA
36.72B
13.65B
38.56B
38.37B
Gain or loss from assets sale
5.12M
3.00K
-10.00M
3.00K
AI content may include mistakes. Learn more
Google apps